Blood Test Could Detect Heart and Kidney Disease Earlier
Researchers at the University of Bristol have developed a blood test that detects early damage to microscopic blood vessels by analyzing changes in the glycocalyx coating on red blood cells, offering potential for earlier diagnosis of heart and kidney disease. The study suggests this non-invasive method could transform preventative healthcare by identifying vascular damage before symptoms appear or become irreversible.
Scientists at the University of Bristol have discovered a way to detect early vascular damage through a simple blood test, potentially revolutionizing the early diagnosis of heart and kidney disease. The team identified that damage to the glycocalyx—a sugar- and protein-rich coating on blood vessel linings—leaves a biochemical imprint on red blood cells as they circulate. This imprint reflects the condition of the vessel walls, allowing doctors to assess microscopic blood vessel health without invasive procedures. Previously, diagnosing vascular damage required tissue biopsies or advanced microscopy, which are impractical for routine use. The new method leverages chemical techniques to track glycocalyx transfer onto red blood cells, providing an early marker of disease before other indicators become detectable. Researchers found this approach could also monitor treatment effectiveness by rapidly detecting when drugs restore blood vessel integrity. Dr. Matthew Butler, lead author and MRC Clinician Scientist at the University of Bristol, emphasized the potential impact of the discovery. He stated that the method could transform disease detection by identifying vascular damage before it progresses to irreversible stages. The findings were published as part of a study exploring how changes on red blood cell surfaces mirror the health of tiny, previously inaccessible blood vessels. Professor Simon Satchell, last author and Professor of Renal and Vascular Medicine, added that the breakthrough could enable proactive healthcare by catching issues early. Kidney Research UK’s Chief Research Officer, Dr. David Crosby, praised the research, noting its potential to link cardiovascular and kidney health through a novel diagnostic approach. The study suggests this blood test could become a standard tool for assessing disease risk, particularly for heart and kidney conditions that together account for one in three global deaths. Researchers are now exploring further applications, including monitoring therapeutic interventions in real time.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.